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Background: Neonatal hyperbilirubinemia has traditionally been screened by either total serum bilirubin or
transcutaneous bilirubin. Whole blood bilirubin (TwB) by the GEM Premier 4000® blood gas analyzer (GEM) is a
relatively new technology and it provides fast bilirubin results with a small sample volume and can measure co-
oximetry and other analytes. Our clinical study was to evaluate the reliability of TwB measured by the GEM and identify
analytical and clinical factors that may contribute to possible bias.
Methods: 440 consecutive healthy newborn samples that had plasma bilirubin ordered for neonatal hyperbilirubinemia
screening were included. TwB was first measured using the GEM, after which the remainder of the blood was spun and
plasma neonatal bilirubin was measured using the VITROS 5600® (VITROS).
Results: 62 samples (14%) were excluded from analysis due to failure in obtaining GEM results. Passing-Bablok regression
suggested that the GEM results were negatively biased at low concentrations of bilirubin and positively biased at higher
concentrations relative to the VITROS results (y= 1.43x-61.13). Bland-Altman plots showed an overall negative bias of the
GEM bilirubin with a wide range of differences compared to VITROS. Both hemoglobin concentration and hemolysis
affected the accuracy of the GEM results. Clinically, male infants had higher mean bilirubin levels, and infants delivered by
caesarean section had lower hemoglobin levels. When comparing the number of results below the 40th percentile and
above the 95th percentile cut-offs in the Bhutani nomogram which would trigger discharge or treatment, GEM bilirubin
exhibited poor sensitivity and poor specificity in contrast to VITROS bilirubin.
Conclusions: An imperfect correlation was observed between whole blood bilirubin measured on the GEM4000® and
plasma bilirubin on the VITROS 5600®. The contributors to the observed differences between the two instruments were
specimen hemolysis and the accuracy of hemoglobin measurements, the latter of which affects the calculation of
plasma-equivalent bilirubin. Additionally, the lack of standardization of total bilirubin calibration particularly in newborn
specimens, may also account for some of the disagreement in results.
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Jaundice is the most common condition that requires
medical attention in newborns. Although it is benign
and transient in most cases, some neonates with severe
hyperbilirubinemia are at risk for bilirubin-induced
neurologic dysfunction (BIND), which occurs when* Correspondence: li.wang@cw.bc.ca
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and binds to brain tissue causing irreversible neurologic
damage if left untreated [1]. Prevention of BIND
requires appropriate clinical assessment for risk factors,
timely measurement of bilirubin levels and early treat-
ment with either phototherapy or exchange transfusion
[2]. Universal screening for newborn hyperbilirubinemia
by measuring either total serum bilirubin (TSB) or trans-
cutaneous bilirubin (TcB) has been adopted by many
countries [3]. TSB has been the clinical standard for
determining risk for kernicterus since the publication ofle is distributed under the terms of the Creative Commons Attribution 4.0
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high bilirubin levels and may be affected by skin
pigmentation (although improved with newer models)
and skin thickening, making it unsuitable for older
neonates [5, 6]. Most importantly, TcB is a physiolo-
gically different parameter than TSB because TcB as-
sesses mainly extravascular bilirubin whereas TSB
reflects the intravascular bilirubin concentration [6].
Whole blood bilirubin (TwB) analyzed on a blood gas
instrument is a new and promising alternate method for
neonatal hyperbilirubinemia screening. Compared to
TSB it requires a smaller sample volume, has a faster
turnaround time, and offers concurrent measurement of
a full range of analytes (blood gas, electrolytes, glucose,
lactate and co-oximetry), which allows for an efficient
and comprehensive assessment of newborn status espe-
cially in critically ill neonates. Given these potential
advantages of TwB, we conducted a prospective clinical
study to compare TwB to TSB in the laboratory. Our
objectives were to compare TwB results on the GEM
Premier 4000® blood gas analyzer (Instrumentation
Laboratory, Bedford, MA) (GEM) against plasma neo-
natal bilirubin results on the VITROS 5600® (Ortho
Clinical Diagnostics, Rochester, NY) (VITROS) and to
examine whether bilirubin measurement is influenced by
various pre-analytical, analytical or clinical factors.
Methods
Patients
Three hundred and thirty-one newborns for whom bili-
rubin testing was clinically required were enrolled
between May and August 2014 (total of 440 samples as
some neonates had multiple samples). The inclusion cri-
teria were for the neonates to be <14 days postnatal age
and that sufficient blood volume was collected to enable
measurement of both whole blood and plasma bilirubin.
Capillary whole blood samples were collected into plain
heparinized microtainers. TwB was measured using the
GEM after which the remainder of the specimen was
centrifuged and the clinically required plasma neonatal
bilirubin was measured using the unconjugated and con-
jugated bilirubin (BuBc) slide on the VITROS. Clinical
data such as gestational age, gender, birth weight, post-
natal age, Apgar score and delivery methods (caesarean
section (CS) vs vaginal delivery) were extracted from
chart reviews. This study was approved by the Research
Ethics Committee of the University of British Columbia
(H13-02615). Consent was not required as this was a
quality assessment project in the lab and no additional
blood was drawn.
Laboratory analysis principles
TwB measured by the GEM is a point-of-care test that
was approved by the Federal Drug Administration in2010. The blood gas analyzer measures total bilirubin
along with the hemoglobin (Hb) fractions in hemolyzed
whole blood samples by direct spectrophotometry in the
co-oximetry module. In order to distinguish each com-
ponent, multi-wavelengths are used and multi-variate
regression algorithms established in a spectral library are
compared when measuring a whole blood sample.
Plasma equivalent bilirubin results are then reported
using a formula [Bili plasma = bili whole blood/
(1-hematocrit)], and hematocrit (Hct) is calculated as
[Hct = 0.03x Hb]. The constant 0.03 represents the aver-
age concentration of hemoglobin (g/dL) within the red
blood cells. GEM bilirubin is calibrated based on total
bilirubin spectrum made of known levels of conjugated
and unconjugated bilirubin. Since the GEM uses a direct
spectrophotometric assay, it cannot distinguish different
fractions of bilirubin.
Neonatal bilirubin concentrations in heparinized plasma
were measured using the multi-layered slide technique by
reflectance spectrophotometry on a VITROS 5600®
analyzer. In the BuBc slide, plasma distributes and reacts
with reagents while Hb and other interfering compounds
are trapped and masked from being measured. Bu and Bc
are measured simultaneously. The VITROS calibrator is
composed of high grades of Bu that is traceable to NIST
916a and the synthetic ditaurobilirubin disodium salt for
Bc. The Hemolysis index (H index) is a quantitative esti-
mate of Hb that can be measured spectrophotometrically
using the VITROS and was used to assess the effect of
hemolysis on the measurement of whole blood bilirubin
by the GEM.
Statistical analysis
The study population was characterized by descriptive
statistics. Passing-Bablok regression, Bland-Altman plots
[7], and paired sample t-tests were used to examine the
differences between the whole blood bilirubin (GEM)
and BuBc measurements (VITROS). To determine the
relationship between the difference in measurements by
the GEM and the VITROS and clinical factors such as
gestational age, gender, birth weight, Apgar score and
delivery mode, we used Welch’s t-tests for comparisons
between two groups, ANOVA for comparisons among
more than two groups, and linear regression for relation-
ships with continuous variables. Apgar scores were
dichotomized into <7 and ≥7 groups for comparison. All
comparisons of the above clinical variables were con-
ducted on the first sample from each neonate.
We used generalized additive modeling to describe
the association between the difference in methods and
Hb concentration (as the relationship was clearly non-
linear) and linear modeling to describe the association
between the difference in methods and hemolysis (H
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some neonates.
Finally, we assessed the predictive value of the GEM
whole blood bilirubin results by applying the Bhutani
nomogram [4] to classify them into the different risk
categories. We also classified the VITROS values against
the nomogram and used the numbers in each of the risk
categories as the standard against which to compare the
GEM results. We calculated sensitivity, specificity,
negative predictive value (NPV), and positive predictive
value (PPV) for risk cutoffs at the <40th percentile and
>95th percentile, which would trigger discharge and
treatment, respectively. Analyses were carried out using
R version 3.2.4.Results
Demographic
Table 1 shows the demographic and clinical variables of
the study population. There were a total of 440 samples
(from 331 newborns) collected during the study period.
Three hundred and seventy eight samples (86%) were in-
cluded in the analysis while 62 samples (14%) were ex-
cluded because the instrument reported whole blood
bilirubin and/or co-oximetry results as incalculable.
Among these 378 samples (from 318 neonates), 60
neonates had multiple bilirubin samples collected. The
mean gestational age was 38.8 weeks and median post-
natal age was 48 h. In total, 41% of neonates were deliv-
ered by CS while 59% were vaginal deliveries. Fifty-three
percent of the study population was male.500Passing-bablok regression
The Passing-Bablok linear regression estimated the sys-
tematic difference (intercept) and proportional differ-
ence (slope) between the GEM and the VITROS (Fig. 1).
There was a significant underestimation of bilirubinTable 1 Demographic and clinical variables of the 318 unique
neonates
Variable
Gestational age (weeks), mean (SD) 38.8 (2.0)
Postnatal age (hours), median (IQR)a 48 (24–72)




APGAR at 1 min <7 21 [8%]
median (IQR) 9 (8–9)
APGAR at 5 min <7 10 [4%]
median (IQR) 9 (9–9)
aFor all samplesconcentration with the GEM method at low bilirubin
concentrations, whereas at bilirubin concentrations
greater than 142 umol/L, the GEM method tended to
overestimate bilirubin concentrations relative to the
VITROS method. The regression equation was: y = 1.43x-
61.13 (95% CI: 1.36 to 1.50 for the slope, and −73.8
umol/L to −50.5 umol/L for the y-intercept).Bland-Altman plot
The Bland-Altman analysis estimated a mean bias of −0.14
umol/L (95% Limits of agreement = −81.6 umol/L to 81.3
umol/L) over the range of bilirubin concentrations tested.
The minimum bilirubin was 25 umol/L, and the maximum
bilirubin was 361 umol/L (Fig. 2). Although the mean
difference (bias) is near zero, the GEM values underesti-
mate at low concentrations of bilirubin and overestimate at
higher concentrations, as revealed by the Passing-Bablok
regression above.Hemoglobin effects/hemolysis effects
The total Hb concentration in the study population
ranged between 122 g/L to 230 g/L with a mean concen-
tration of 195 g/L. No difference was detected in Hb
concentrations between male (Mean: 195.8 g/L, SD =
19.8) and female infants (Mean = 195.3 g/L, SD = 18.3).
Fig. 3a demonstrates the effect of Hb concentration on
the measurement of whole blood bilirubin using the
GEM method. The GEM bilirubin method tended to
overestimate bilirubin when Hb was relatively low and
underestimate it when Hb concentrations were high.
The generalized additive model provided a much better
fit to the data compared to a linear model (F test on
change in deviance, p < 0.001) with an estimated number




















Intercept = -61.13 [-73.75 : -50.45]
Slope = 1.426 [1.361 :   1.5]
Fig. 1 Comparison of results by Passing-Bablok regression. The solid
line indicates the unbiased estimates of the intercept and slope from
the regression. The grey indicates the 95%CI around those estimates.
The dashed line shows the 1:1 line




































































Fig. 3 a The hemoglobin effect on the difference between GEM
and VITROS: relationship between hemoglobin and the difference in
bilirubin estimated by the two methods. The solid line indicates the
additive model fit, and the dashed lines indicate the 95% confidence
intervals. b. The hemolysis effect on the difference between GEM
and VITROS: relationship between hemolysis (H index) and the
difference in bilirubin estimated by the two methods. The solid
line indicates the linear model fit, and the dashed lines indicate
the 95% confidence intervals



































Fig. 2 Bland-Altman plot. The solid line indicates the estimated bias
and the dashed lines indicate the 95% limits of agreement
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concentration at Hb concentrations up to 200 g/L at
which point it begins to strongly underestimate the bili-
rubin concentration. Fig. 3b demonstrates the effect of
hemolysis on the measurement of whole blood bilirubin
with the GEM method. Similar to Hb concentration,
specimens with more hemolysis demonstrated a greater
underestimation of bilirubin with the GEM methodology
compared to the VITROS BuBc (slope = −0.4, p < 0.001).
Clinical factors contributing to the differences in bilirubin
measurement between the GEM and VITROS methods
A statistically significant difference in bilirubin levels
was detected between male and female infants. When
plasma bilirubin was measured using the BuBc slide,
male infants had higher levels with an average concen-
tration of 163.5 umol/L and standard deviation of 58.2
umol/L than female infants with an average of 143.4
umol/L and a standard deviation of 52.1 umol/L
(Welch’s t = −3.2, df = 313, p = 0.001). A significant dif-
ference in whole blood bilirubin levels between male
and female infants (Welch’s t = −3.2, df = 312.9, p =
0.002) was also detected when measured with the GEM
methodology. Similar to the BuBc slide, male infants had
higher whole blood bilirubin concentrations when com-
pared to female infants (162.9 umol/L for male; 136.1
umol/L for female) when measured with the GEM
method. Although method differences were observed in
gender specific bilirubin levels, these differences were
not statistically significant.
Similarly, we found that there were no significant ef-
fects of mode of delivery, gestational age, birth weight
and Apgar scores on the difference between the two
methods (data not shown). However, we found that
there was a significant difference in the mean Hb
concentrations in neonates delivered by CS in comparisonto those delivered vaginally (Welch's t = −2.86, df = 230.1,
p = 0.005). Babies born via CS had lower hemoglobin
levels on average (190.8 g/L vs 197.7 g/L).
Sensitivity, specificity, and predictive values for VITROS
nomogram vs GEM nomogram
We examined the potential impact on clinical interpret-
ation by comparing bilirubin results produced by the
GEM versus the VITROS against the Bhutani nomo-
gram. Five results from the dataset had to be excluded
from this analysis because the time of collection was not
known. For comparisons at the >95th percentile level,
which would trigger treatment, the sensitivity (true
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was 84%, positive predictive value (PPV) was 46%, and
the negative predictive value (NPV) was 92% (Table 2);
while for comparisons at the <40th percentile which
would trigger discharge, the sensitivity was 78%, specifi-
city was 79%, PPV was 61%, and NPV was 90%
(Table 3).
Discussion
This clinical study compared the bilirubin measurements
between the whole blood GEM methodology and the
plasma VITROS BuBc slide methodology in healthy
newborns with capillary samples. We found an imperfect
correlation between TwB and neonatal bilirubin such
that bilirubin levels were underestimated at low concen-
trations by the GEM method while at concentrations
greater than 142 umol/L, the GEM method tended to
overestimate relative to the VITROS method. When
classifying the risks for neonatal hyperbilirubinemia
based on the Bhutani nomogram with these two
methods, GEM exhibited low sensitivity and low positive
predictive value in comparison to VITROS. Many factors
including pre-analytical, analytical and clinical may have
contributed to the observed differences between the
methods.
First, although TwB is measured, the instrument re-
ports plasma equivalent bilirubin using a calculation that
relies on the measurement of Hb. While this conversion
facilitates comparison with the Bhutani nomogram for
risk stratification, inaccurate Hb leads to inaccurate
plasma equivalent bilirubin results. Additionally, TwB
was unreportable in 14% of samples because Hb was
outside of the manufacturer’s claimed measurable range
(30 g/L - 230 g/L). This observation could be related to
the methodology used by the GEM to measure Hb or
pre-analytical factors such as microclot formation due to
poor sample mixing which may have affected the accur-
acy of the co-oximetry with falsely high Hb results.
Interestingly, we did find that healthy term newborns
within the first 2 days of life have higher normal Hb
levels up to 239 g/L [8]. Neonatal Hb levels may be even
higher due to polycythemia or other conditions and this
will definitely challenge the analytical range of Hb by the
GEM methodology (upper analytical range is 230 g/L).
Specimens with Hb exceeding the 230 g/L will lead to a
failure in generating a bilirubin result and a high failureTable 2 GEM results of >95th percentile on the Bhutani nomogram
VITROS r
Positive
GEM results Positive (treatment) 42 (true
Negative (no treatment) 23 (false
65rate would be problematic for a diagnostic device being
considered as a screening tool. We also found that
hemolysis can affect the difference between the GEM
and the VITROS. Since all whole blood samples have to
be hemolyzed before co-oximetry analysis, it is puzzling
why hemolysis can affect accuracy. Based on the similar
trends observed for both hemoglobin effect and hemolysis
effect, we postulate this is just another reflection that high
Hb concentration in the hemolyzed specimen can affect
accuracy.
Second, the difference between results by the two
methods might be related to differences in calibration.
The GEM bilirubin is calibrated to total bilirubin,
whereas the BuBc slides on the VITROS is calibrated to
the respective fractions. Two tests are available from
Ortho Diagnostics: neonatal bilirubin (BuBc) and total
bilirubin (TBIL) [9], with BuBc being recommended for
testing in neonates under 2 weeks of age and TBIL for
patients 15 days old and above by the manufacturer [9].
The sum of Bu and Bc is not the same as total bilirubin
because the latter contains not only Bu and Bc, but also
delta bilirubin which is a bilirubin covalently bounded
with albumin. Due to the lack of interference by Hb
[10], the simultaneous measurement of Bu and Bc, and
the absence of a clinically significant difference between
BuBc and total bilirubin measurements in newborns (ne-
onates have <2% delta bilirubin) [11, 12], we only offer
BuBc in our hospital to avoid clinician confusion. Com-
mercial calibrators used by field methods are known to
affect the accuracy of bilirubin measurements on chem-
istry analyzers [13] and the clinical impact by different
calibrators has been published recently. Kuzniewicz et al.
[14] reported that the recalibration of the BuBc method
by the manufacturer in 2012 led to a 39% relative reduc-
tion in infants with a TSB level of 257 umol/L and more
than 50% reduction in both birth hospital phototherapy
and readmissions for phototherapy. Similarly, the imple-
mentation of a new formulation of total bilirubin by
another manufacturer (Roche diagnostics) also affected
neonatal phototherapy rates even compared to its previ-
ous formulation [15]. Our comparison of GEM total bili-
rubin to BuBc instead of TBIL would add another
challenge for the comparison with the whole blood bili-
rubin method by GEM. Standardization is needed for all
bilirubin methods, which would improve the care for
neonatal hyperbilirubinemia and allow for neonates tocompared to VITROS results of >95th percentile
esults Totals
(treatment) Negative (no treatment)
positives) 50 (false positives) 92
negatives) 258 (true negatives) 281
308
Table 3 GEM results of <40th percentile on the Bhutani nomogram compared to VITROS results of >95th percentile
VITROS results Totals
Positive (discharge) Negative (no discharge)
GEM results Positive (discharge) 87 (true positives) 55 (false positives) 142
Negative (no discharge) 24 (false negatives) 207 (true negatives) 231
111 262
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of their disease.
We also analyzed possible contributing clinical factors
to the observed differences in the methods and found a
significant difference between methods for male and
female infants. Additionally, we found that male infants
had higher bilirubin levels than female infants in our
patient population, which supports a previous report
that male gender is associated with a higher risk of
developing hyperbilirubinemia [16]. This suggests that
the relationship between the difference in the methods
and infant sex was at least partially driven by the rela-
tionship between average bilirubin levels and infant sex.
For comparisons at the >95th percentile level which
would trigger treatment, sensitivity and PPV were 65
and 46%, respectively. These results suggest that had
GEM bilirubin been used as the screening tool for risk
stratification based on the Bhutani nomogram, 35% of
neonates that would have been treated by VITROS re-
sults would not have been treated by the GEM results.
Similarly, for low risk neonates (<40th percentile), who
can be safely discharged, the sensitivity and PPV were 78
and 61%, respectively. This suggests that only 61% of
those low-risk levels by GEM would be classified as low-
risk by VITROS. These results support the conclusion
that GEM bilirubin is neither sensitive nor specific
enough to screen for neonatal hyperbilirubinemia.
Finally, we found that neonates delivered by CS had
lower Hb concentrations than neonates delivered vagi-
nally. This is consistent with the previous finding that
neonates post vaginal deliveries have higher hemoglobin
levels which could be due to the recommendation of de-
layed cord clamping which increases placental-fetal
transfusion [17], whereas the duration of placental trans-
fusion in CS tends to be shorter since an immediate
cord clamping is often performed to avoid maternal
bleeding, infections or other surgery-related complica-
tions [18]. A systematic review and meta-analysis study
also indicated that CS compared with vaginal delivery,
was associated with an increased placental residual
blood volume which would cause a decreased level of
hematological indices including hemoglobins in the neo-
nates [19]. These interesting findings could be achieved in
this study because of the availability of Hb measurements
by whole blood gas analyzers. This is extremely useful
when caring for babies with hyperbilirubinemia due tohemolytic causes as simultaneous availability of whole
blood bilirubin and Hb results would reduce the total
blood volume and time needed for both tests in the lab.
Conclusions
This study suggests that TwB by the GEM is not yet ready
for neonatal hyperbilirubinemia screening. Handling the
difficult matrix of whole blood samples from newborns
requires technological improvements to control pre-
analytical and analytical variables. Ultimately, improvement
of total bilirubin calibration with standardization and the
accuracy of Hb measurements will help TwB become
utilized clinically. With technical improvement, we believe
whole blood bilirubin has the potential to become a valid
screening tool considering the benefits of having additional
analytes especially hemoglobin.
Abbreviations
Bc: Conjugated bilirubin; Bu: Unconjugated bilirubin; CS: Caesarean section;
GEM: GEM Premier 4000® blood gas analyzer; Hb: Hemoglobin; Hct: Hematocrit;
TSB: Total serum bilirubin; TwB: Whole blood bilirubin; VITROS: VITROS 5600®
Acknowledgements
We gratefully acknowledge the mentorship of Dr. Cathy Halstead and the
keen assistance of the medical laboratory technologists and assistants of the
chemistry lab, especially Ms. Leslie Trowski. We also thank Michelle Dittrick
for REB application and two nursing students: Abraham Cabaccang & Anita
Wong for collecting demographic data of the study.
Funding
No internal or external funding for this manuscript.
Availability of data and materials
The datasets used and/or analysed during the current study available from
the corresponding author on reasonable request.
Authors’ contributions
LW conceptualized and designed the study, drafted the initial manuscript, and
approved the final manuscript as submitted; AA carried out the initial analyses,
reviewed and revised the manuscript, and approved the final manuscript as
submitted; BJ, KH and ML were involved in the interpretation of data, revising
the manuscript and approved the final manuscript as submitted; MB designed
the data collection sheets, coordinated and supervised data collection, critically
reviewed the manuscript, and approved the final manuscript as submitted.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
This study was approved by the Research Ethics Committee of the University
of British Columbia (H13-02615). Consent was not required as this was a
quality assessment project in the lab and no additional blood was drawn.
Wang et al. BMC Pediatrics  (2017) 17:92 Page 7 of 7Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1BC Children’s & Women’s Hospital, University of British Columbia, 4500 Oak
Street, Room 2J9, Vancouver, BC V6H 3 N1, Canada. 2Women’s Health
Research Institute, Children’s and Women’s Health Centre of British
Columbia, University of British Columbia, Vancouver, Canada. 3Department of
Pediatrics, Children’s and Women’s Health Centre of British Columbia,
University of British Columbia, Vancouver, Canada. 4Department of Pathology
and Laboratory Medicine, Royal University Hospital, Saskatoon Health Region,
University of Saskatchewan, Saskatoon, Canada. 5Perinatal Health Program,
Department of Obstetrics and Gynecology, Children’s and Women’s Health
Centre of British Columbia, University of British Columbia, Vancouver, Canada.
6BC Children’s Hospital Research Institute, University of British Columbia,
Vancouver, BC, Canada.
Received: 7 November 2016 Accepted: 21 March 2017References
1. Shapiro SM. Definition of the clinical spectrum of kernicterus and bilirubin-
induced neurologic dysfunction (BIND). J Perinatol. 2005;25(1):54–9.
2. American Academy of Pediatrics Subcommittee on Hyperbilirubinemia.
Management of hyperbilirubinemia in the newborn infant 35 or more
weeks of gestation. Pediatrics. 2004;114(1):297–316.
3. Raimondi F, Ferrara T, Borrelli AC, Schettino D, Parrella C, Capasso L.
Neonatal hyperbilirubinemia: a critical appraisal of current guidelines and
evidence. J Pediatr Neonatal individualized Med. 2012;1(1):25–32.
4. Bhutani VK, Johnson L, Sivieri EM. Predictive ability of a predischarge hour-
specific serum bilirubin for subsequent significant hyperbilirubinemia in
healthy term and near-term newborns. Pediatrics. 1999;103(1):6–14.
5. El-Beshbishi SN, Shattuck KE, Mohammad AA, Petersen JR.
Hyperbilirubinemia and transcutaneous bilirubinometry. Clin Chem.
2009;55(7):1280–7.
6. Bosschaart N, Kok JH, Newsum AM, Ouweneel DM, Mentink R, van Leeuwen
TG, Aalders MC. Limitations and opportunities of transcutaneous bilirubin
measurements. Pediatrics. 2012;129(4):689–94.
7. Bland JM, Altman DG. Statistical methods for assessing agreement between
two methods of clinical measurement. Lancet. 1986;1(8476):307–10.
8. Cousineau J, Anctil S, Carceller A, Gonthier M, Delvin EE. Neonate capillary
blood gas reference values. Clin Biochem. 2005;38(10):905–7.
9. VITROS Chemistry Products BuBc Slides, TBIL Slides and Bilirubin
Supplement [Package inserts]. http://techdocs.orthoclinical.com/TechDocs/
TechDocSearch.aspx?tID=0&culture=en-ca. Accessed 4 Nov 2016.
10. Lo SF, Jendrzejczak B, Doumas BT. Total or neonatal bilirubin assays in the
Vitros 5,1 FS: hemoglobin interference, hemolysis, icterus index. Clin Chem.
2007;53(4):799–800.
11. Langbaum ME, Farber SJ, Rosenthal P. Automated total and neonatal
bilirubin values in newborns: is a distinction clinically relevant? Clin Chem.
1992;38(9):1690–3.
12. Brett EM, Hicks JM, Powers DM, Rand RN. Delta bilirubin in serum of pediatric
patients: correlations with age and disease. Clin Chem. 1984;30(9):1561–4.
13. Lo SF, Doumas BT. The status of bilirubin measurements in U.S. laboratories:
why is accuracy elusive? Semin Perinatol. 2011;35(3):141–7.
14. Kuzniewicz MW, Greene DN, Walsh EM, McCulloch CE, Newman TB.
Association between laboratory calibration of a serum bilirubin assay,
neonatal bilirubin levels, and phototherapy use. JAMA Pediatr.
2016;170(6):557–61.
15. Lyon ME, Baerg KL, Olson TN, Agnew BL, Smith-Fehr JC, Lyon AW. The
clinical impact of implementing the Roche® bilirubin total Gen.3 method on
neonate phototherapy. Clin Biochem. 2015;48(16–17):1171–3.
16. Newman TB, Xiong B, Gonzales VM, Escobar GJ. Prediction and prevention
of extreme neonatal hyperbilirubinemia in a mature health maintenance
organization. Arch Pediatr Adolesc Med. 2000;154(11):1140–7.
17. World Health Organization. WHO recommendations for the prevention and
treatment of postpartum haemorrhage. http://apps.who.int/iris/bitstream/
10665/75411/1/9789241548502_eng.pdf. Accessed 4 Nov 2016.18. Shirvani F, Radfar M, Hashemieh M, Soltanzadeh MH, Khaledi H, Mogadam
MA. Effect of timing of umbilical cord clamp on newborns’ iron status and
its relation to delivery type. Arch Iran Med. 2010;13(5):420–5.
19. Zhou YB, Li HT, Zhu LP, Liu JM. Impact of cesarean section on placental
transfusion and iron-related hematological indices in term neonates a
systemic review and meta-analysis. Placenta. 2014;35(1):1–8.•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
